INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has affected a huge number of people for 2 years worldwide, becoming the major public health issue and forcing healthcare facilities to reorganize medical units, including obstetrical and gynecologic activities.™

Pregnancy is considered an independent risk factor for adverse outcome in women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with increased rates of maternal mortality and intensive care unit admissions compared with
MATERIALS AND METHODS

2.1 | Study protocol

The present review was performed according to a protocol recommended for systematic review. The study was reported according to the Preferred Reporting Item for Systematic Reviews and Meta-analyses (PRISMA) statement and Meta-analysis Of Observational Studies in Epidemiology (MOOSE). PRISMA and MOOSE checklists are reported in Tables S1 and S2. It was also registered on PROSPERO (CRD42022319270). All review stages were conducted independently by three authors. In particular, three authors (OG, MGT, GGI) independently assessed electronic search, eligibility of the studies, inclusion criteria, risk of bias, and data extraction; RDG and AR performed the data analysis. All disagreements were resolved by discussion with the senior author (GMM).

2.2 | Literature search and study selection

The literature search was conducted using Web of Science, Scopus, ClinicalTrial.gov, MEDLINE, Embase, OVID, and Cochrane Library as electronic databases. The studies were identified with the use of a combination of the following text words: “coronavirus” OR “COVID-19 pandemic” OR “SARS-CoV-2” OR “COVID-19” AND “vaccine” OR “vaccination” OR “COVID-19 vaccine” OR “SARS-CoV-2 vaccine” AND “pregnancy” OR “pregnant” OR “pregnant women” OR “during pregnancy” OR “pregnancy outcome” OR “adverse outcome” from December 2019 to February 28, 2022. Review of articles also included the abstracts of all references retrieved from the search. Duplications were removed using Endnote online software and also manually. Only English-language studies were considered for inclusion. Unpublished or non-peer-reviewed studies were not included. Given that, for ethical reasons, no randomized controlled studies were planned in pregnant women, we included in our systematic review all observational studies that evaluated the population of women undergoing SARS-CoV-2 vaccination during the COVID-19 pandemic and compared pregnancy, maternal, and fetal-neonatal outcomes with those of non-vaccinated pregnant women. We excluded case reports and studies without control groups or that considered non-pregnant women as controls, as well as studies focusing only on immunogenic properties or intrinsic adverse events of vaccines against SARS-CoV-2 infection.

2.3 | Risk of bias assessment

The risk of bias and quality assessment of the included studies were performed using the Newcastle-Ottawa Scale (NOS). The NOS score was used to evaluate the included studies, and judgment on each one was passed according to three issues: selection of the study group, comparability between groups, and ascertainment of exposed/unexposed cohorts.

2.4 | Data extraction

Data were extracted from the included studies without modifications. A data extraction sheet based on the Cochrane data extraction template for non-randomized controlled trials was used (https://dplp.cochrane.org/data-extraction-forms). The main data extracted for our systematic review were: first authors’ names and publication year, study design, study location, period considered in the analysis, sample size, inclusion and exclusion criteria, type of vaccine, general features of included populations (age, body mass index, race, previous disease, obstetrical history, number of fetuses, trimester of vaccination) as well as various maternal, fetal, and neonatal outcomes.
2.5 | Outcomes

The primary outcome was the evaluation of risk of small-for-gestational-age fetuses for pregnant women receiving SARS-CoV-2 vaccine. Other gestational diseases, delivery outcomes, neonatal birth weight, and fetal-neonatal conditions were considered as secondary outcomes.

2.6 | Statistical analysis

Prevalence of SARS-CoV-2 vaccination according to trimester of pregnancy was calculated as the number of pregnant women vaccinated in that specific trimester: first, second, and third, respectively. Also, the association between the prevalence of sociodemographic or adverse pregnancy outcome with SARS-CoV-2 vaccine was assessed using odds ratio (OR) with 95% confidence interval (CI), whereas for continuous variables, results were expressed as mean difference (MD) with their 95% CI. All analyses were performed by adopting the random effect model of DerSimonian and Laird. Statistical heterogeneity among included studies was evaluated by the inconsistency index $I^2$. In detail, heterogeneity was classified as: null for $I^2 = 0\%$, minimal for $I^2 < 25\%$, low for $I^2 < 50\%$, moderate for $I^2 < 75\%$, and high for $I^2 \geq 75\%$. Egger’s test and tests for funnel plot asymmetry to assess potential publication bias were not used when the total number of publications included for each outcome was less than 10, as the tests lack power to detect real asymmetry in this case. Comprehensive Meta-Analysis (BIOSTAT, Englewood, NJ, USA) and REVIEW MANAGER 5.3 (Copenhagen: The Nordic Cochrane Centre, Cochrane Collaboration, 2014) were used as data analysis software. A $P$ value less than 0.05 was considered significant.

3 | RESULTS

3.1 | Study selection and study characteristics

We identified 1037 articles, 40 of which were assessed with respect to their eligibility for inclusion and nine studies were included in the systematic review (Table 1; Figure 1). Excluded studies and reason for exclusion are reported in Table S3.

These nine studies included 40728 pregnant women, 21289 (52.3%) of whom received the COVID-19 vaccine, while 19431 (47.7%) pregnant women did not receive it. The majority of studies were performed in Israel \cite{33–37} and the USA \cite{38,39}; one study was performed in Romania \cite{30} and another in the UK \cite{41} Only two studies were prospective \cite{38,40}, whereas the others were retrospective observational analyses. Only three studies evaluated cohorts of women including vaccines others than mRNA-based: Blakeway et al. \cite{41} also described 13 women vaccinated with the AstraZeneca vaccine, and Theiler et al. \cite{39} and Citu et al. \cite{40} observed one woman and 58 women, respectively, who were vaccinated with Janssen.

The results of the quality assessment of the included studies using NOS scale are presented in Table S4. The included studies showed an overall good score regarding the selection of the study groups and for ascertainment of the outcome of interest.

3.2 | Synthesis of the results

Complete general and demographic analysis of study populations was reported in Table 2. We observed that pregnant women who underwent the vaccination were slightly, but significantly, older than those who did not undergo vaccination (OR 0.79, 95% CI 0.14–1.45; $P = 0.020$) and more frequently had a history of miscarriage (OR 1.28, 95% CI 1.06–1.55; $P = 0.009$). Furthermore, Caucasian ethnicity appeared to be associated with vaccination (OR 1.76, 95% CI 1.20–2.58; $P = 0.004$), while women with black ethnicity seemed to refuse it (OR 0.40, 95% CI 0.19–0.81; $P = 0.010$). In the pooled analysis of other anamnestic factors, we did not observe other statistically significant differences (Table 2).

Stratifying per trimester we observed that the majority of the women were vaccinated during the third trimester (Table 3). Looking to maternal outcomes, we noticed that the gestational age at delivery was slightly reduced in pregnant women who were vaccinated compared with unvaccinated women (MD −0.13, 95% CI −0.21 to −0.04; $P = 0.003$) (Figure 2) but actually, SARS-CoV-2 vaccine is associated with a reduced probability of premature delivery (OR 0.88, 95% CI 0.78–0.98; $P = 0.020$) (Figure 3; Table 4). There is no difference in the probability of having a small-for-gestational-age fetus between vaccinated and unvaccinated women (OR 0.97, 95% CI 0.85–1.09; $P = 0.570$), but we observed a reduced probability of a non-reassuring fetal monitoring in pregnant women who received the SARS-CoV-2 vaccine (OR 0.69, 95% CI 0.51–0.94; $P = 0.020$) (Figure 4; Table 5). There were no statistically significant differences in all other explored maternal and fetal-neonatal outcomes between vaccinated and unvaccinated pregnant women.

4 | DISCUSSION

The SARS-CoV-2 vaccine is not associated with increased risk of having a small-for-gestational-age fetus.

Moreover, we found that vaccination was associated with a reduced probability of premature delivery, although the gestational age at delivery seemed slightly lower when compared with that in unvaccinated pregnant women. Furthermore, we observed reduced probability of non-reassuring fetal monitoring in vaccinated women. The pooled analysis of the nine included studies showed also that the prevalence of older and white pregnant women was higher among vaccinated than unvaccinated women, as well as for women with a previous history of miscarriages. In contrast, black women had a lower prevalence in the vaccinated group.

As far as we know, the present study represents the first pooled analysis for the evaluation of maternal, fetal, and neonatal outcomes...
| Authors           | Location | Period considered         | Study design | Sample size (cases vs control) | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Vaccine type          |
|-------------------|----------|---------------------------|--------------|-------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------|
| Rottenstreich et al. (2022) | Israel   | January 2021 – April 2021 | Retrospective | 1775 (712 vs 1063)            | All women aged 18 years or older, with no documented previous positive SARS-CoV-2 PCR test, who delivered during study period | Undocumented COVID-19 disease or vaccine status, pre-admission COVID-19 virus disease or a positive PCR test resulting during admission and hospitalization | Pfizer-BioNTech       |
| Blakeway et al. (2021) | UK       | March 2021-July 2021      | Retrospective | 1328 (140 vs 1188) of which 524 (131 vs 393) after exclusion of COVID-19 affected cases and PSM | Pregnant women with known vaccination status                                             | Vaccinated entirely before pregnancy or after birth, pregnancies complicated by fetal aneuploidy and genetic syndromes | 109 Pfizer-BioNTech; 18 Moderna; 13 Oxford-AstraZeneca |
| Wainstock et al. (2021) | Israel   | January 2021-June 2021    | Retrospective | 4399 (913 vs 3486)            | Women who delivered singletons at the hospital unit in the period considered           | Diagnosed COVID-19 in the past, multiple gestations or unknown vaccination status and pregnancy follow-up information | Pfizer-BioNTech       |
| Theiler et al. (2021) | USA      | December 2020–April 2021  | Retrospective | 2002 (140 vs 1862) of which 1790 (138 vs 1652) after exclusion of COVID-19 affected cases | Women aged 16–55 years with a delivery event at a hospital in the period considered     | Women who opted out to use their medical records for research                        | 127 Pfizer-BioNTech; 12 Moderna; 1 Janssen |
| Shanes et al. (2021) | USA      | January 2021–April 2021   | Prospective  | 200 (84 vs 116)               | Women who received vaccine delivering during study period                              | NS                                                                                 | mRNA vaccine          |
| Goldshtein et al. (2022) | Israel   | March 2021-September 2021 | Retrospective | 24 190 (16 738 vs 7452) of which 20 864 (15 637 vs 5227) after exclusion of COVID-19 affected cases and IPTW | All singleton live births during study period                                          | Records with no mother-offspring linkage were excluded because it was not feasible to assess their prenatal exposure status Non-singleton live births | Pfizer-BioNTech       |
| Beharier et al. (2021) | Israel   | April 2020–March 2021     | Retrospective | 158 (92 vs 66)                | Age of 18 years or older and a willingness to participate and provide informed consent | Pregnant women with active maternal COVID-19 disease at delivery                     | Pfizer-BioNTech       |
| Dick et al. (2022) | Israel   | December 2020–July 2021   | Retrospective | 5618 (2305 vs 3313)           | Women with singleton deliveries                                                       | Multiple pregnancy, vaccination before pregnancy, COVID-19 infection during or before pregnancy, or unknown timing of vaccination | Pfizer BioNTech or Moderna vaccines |
| Citu et al. (2022)  | Romania  | May 2021–December 2021    | Prospective  | 702 (173 vs 529)             | Women in the third trimester                                                        | NS                                                                                  | 115 Pfizer BioNTech; 58 Janssen |

Abbreviations: COVID-19, coronavirus disease 2019; IPTW, inverse probability of treatment weights; NS, not specified; PCR, polymerase chain reaction; PSM, propensity score matching; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
in women undergoing SARS-CoV-2 vaccination, after exclusion of cases affected by SARS-CoV-2 infection during pregnancy, compared with unvaccinated pregnant women. The main strengths of our analysis are the adherence to PRISMA guidelines and the large number of outcomes considered. The review protocol was not registered a priori. Limitations lie in the observational design and heterogeneity among studies, as well as in the reduced number of studies considering some of the outcomes evaluated. Moreover, more than half of included studies come from a single country, and therefore directionality of the results could be skewed according to local obstetrical policies. Moreover, the differences among the populations of vaccinated and unvaccinated, especially in terms of age, history of miscarriage and ethnicity, could be considered a confounding factor. However, all the effects should eventually determine an increase in perinatal complications of vaccinated pregnant women, which has not been observed, apart from the black ethnicity, which was shown less frequently among vaccinated pregnant women, and we do know that black race is usually linked to increased adverse pregnancy outcomes.42–44

The results of our study reinforce the idea that receiving the SARS-CoV-2 vaccine during pregnancy is not associated with increased probability of adverse outcomes for both mothers and fetus/neonates.

The reduced probability of preterm birth is attributable to the weight of the data from Goldshtein et al.35 which provided the larger data set included in our pooled analysis. Indeed, it could be hypothesized that women who accepted the vaccination were at the same time self-managing their pregnancy in a safe way (i.e. reducing physical stressors), thereby reducing the risk of various complications of pregnancy, such as preterm birth. Lipkind et al.45 observed no increased risk of preterm birth in vaccinated pregnant women compared with their unvaccinated counterparts; in addition, they showed that the prevalence of preterm birth was lower after two doses than after one dose and observed an adjusted OR less than 1 for vaccination in the third trimester, which is consistent with our results. Furthermore, the finding of a reduced probability of non-reassuring fetal heart rate could find explanation in a more preventive

FIGURE 1 Flow diagram of studies identified in the systematic review.
### TABLE 2  General characteristics of study populations expressed as mean difference and pooled odds ratio (with their 95% confidence intervals)

| Studies | Pregnancies | MD (95% CI) | P value | I² |
|---------|-------------|-------------|---------|----|
| Age, years | 9 | 40728 | 0.79 (0.14–1.45) | 0.020 | 98% |
| BMI | 2 | 6946 | 0.17 (-1.07 to 1.42) | 0.780 | 98% |

| Studies | Pregnancies (n₀/N₀ vs n₁/N₁) | Pooled OR (95% CI) | P value | I² |
|---------|-------------------------------|---------------------|---------|----|
| Obesity | 6 | 2115/1816 vs 2273/15580 | 0.97 (0.90–1.04) | 0.380 | 0% |
| Pre-existing disease | 3 | 473/16970 vs 494/9380 | 0.92 (0.79–1.07) | 0.290 | 0% |
| History of miscarriage | 2 | 271/885 vs 382/1592 | 1.28 (1.06–1.55) | 0.009 | 0% |
| IVF | 4 | 370/18676 vs 268/14752 | 2.07 (0.97–4.41) | 0.060 | 93% |
| Nulliparity | 4 | 6315/19895 vs 4034/13690 | 1.05 (0.91–1.20) | 0.510 | 68% |
| Caucasian ethnicity | 2 | 208/280 vs 2079/3050 | 1.76 (1.20–2.58) | 0.004 | 27% |
| Black-Caribbean ethnicity | 2 | 8/280 vs 200/3050 | 0.40 (0.19–0.81) | 0.010 | 0% |
| Asian ethnicity | 2 | 23/280 vs 294/3050 | 0.72 (0.46–1.13) | 0.150 | 0% |
| Mixed ethnicity | 2 | 15/280 vs 284/3050 | 0.43 (0.13–1.44) | 0.170 | 63% |
| Twin pregnancy | 4 | 22/1905 vs 61/7959 | 1.50 (0.86–2.59) | 0.150 | 0% |
| Smoking | 5 | 879/19415 vs 785/13881 | 0.81 (0.47–1.39) | 0.440 | 78% |
| Premature or gestational diabetes | 8 | 826/21213 vs 937/18959 | 1.19 (0.96–1.47) | 0.100 | 61% |

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CI, confidence interval; IVF, in vitro fertilization; MD, mean difference; OR, odds ratio. Statistically significant values are put in bold.

### TABLE 3  Pooled proportions for COVID-19 vaccination stratified per trimester of pregnancy

| Studies | Pregnancies (n/N) | Pooled proportions % (95% CI) | I² |
|---------|-------------------|-------------------------------|----|
| First trimester | 6 | 1863/20981 | 0.78 (0.50–6.00) | 99.6% |
| Second trimester | 6 | 9980/20981 | 10.64 (0.06–35.50) | 99.9% |
| Third trimester | 6 | 9138/20981 | 88.11 (57.80–99.90) | 99.9% |

Abbreviation: CI, confidence interval.

### FIGURE 2  Forest plot for the mean difference of gestational age at delivery.

### FIGURE 3  Forest plot for the odds ratio of preterm delivery.
management by obstetrical practitioners, with the aim of avoiding any suspected risky situations. Nonetheless, we decided to cumulate the data between pregestational and gestational diabetes, considering it as a maternal factor affecting the choice to vaccinate more than a consequence of the vaccine. This decision depends mainly on two reasons: first, there is heterogeneity among the included studies in what they reported, that is if the diabetes was gestational or pregestational, and in the way they reported, mainly in third trimester, so that it is difficult to prove that diabetes is a consequence of the vaccine, given that according to guidelines the diagnosis is made around 24–28 weeks at latest. 46 In detail, Dick et al., 34 Citu et al., 40 and Wainstock et al. 37 describe only gestational diabetes mellitus but it is not specified whether it is diagnosed before or after the vaccine uptake; Beharier et al. 33 and Rottenstreich et al. 36 cumulate gestational and pregestational diabetes mellitus; Goldshtein et al., 35 Blakeway et al., 41 and Theiler et al. 39 differentiate pregestational and gestational diabetes mellitus but the last is not mentioned in the subgroup analyses without COVID-19-affected pregnant women, so we took into consideration only the pregestational one.

Indeed, our results are in accordance with two other systematic reviews and meta-analyses, by Ma et al. 47 and by Pratama et al. 48 Ma et al., 47 performed a pooled analysis of existing literature considering 19078 vaccinated and 21848 unvaccinated pregnant women, and showed that SARS-CoV-2 vaccination appeared to be protective against both the infection and hospitalization due to the infection itself. Pratama et al., 48 in addition to showing similar maternal-fetal and neonatal outcomes between vaccinated and unvaccinated pregnant women, observed a significantly reduced risk of infection only after 10 days from vaccination. However, in contrast to them, we excluded studies that did not properly differentiate (eventually performing subgroup analysis) women affected by SARS-CoV-2 infection during pregnancy from those who had not been affected among the vaccinated and unvaccinated cohorts. In this regard, in fact, we think that the occurrence of COVID-19 during pregnancy could change the management of the cases and therefore pregnancy outcomes could be different, skewing the results.

Apart from being safe in relation to obstetrical and perinatal outcomes, SARS-CoV-2 vaccines are being studied also regarding intrinsic adverse events; Bookstein Peretz et al. 49 showed that non-pregnant women suffer more from adverse events than pregnant women after both first and second doses of vaccine; in addition, they found a lower antibody titer in pregnant women compared with non-pregnant women. Instead, Gray et al. 25 and Collier et al. 26 observed similar levels of antibodies between pregnant and non-pregnant

### Table 4: Pooled odds ratio (95% confidence intervals) for the maternal outcome of women undergoing COVID-19 vaccination compared with unvaccinated women

| Maternal Studies | Pregnancies | MD (95% CI) | P value | I² |
|------------------|-------------|-------------|---------|----|
| Gestational age at delivery | 5 | 12150 | -0.13 (-0.21 to -0.04) | 0.003 | 49% |
| Length of hospitalization | 3 | 4267 | 0.00 (-0.03 to 0.03) | 1.00 | 0% |
| Premature delivery | 6 | 860/19057 vs 700/11850 | 0.88 (0.78–0.98) | 0.020 | 0% |
| Gestational hypertension/pre-eclampsia | 6 | 126/4381 vs 517/11231 | 1.19 (0.86–1.65) | 0.300 | 52% |
| Placental abruption | 4 | 16/1929 vs 54/5471 | 0.66 (0.38–1.16) | 0.150 | 0% |
| Vaginal delivery | 5 | 1506/1978 vs 5004/6710 | 0.96 (0.81–1.13) | 0.600 | 32% |
| Instrumental vaginal delivery | 5 | 85/2067 vs 333/7123 | 0.87 (0.59–1.28) | 0.480 | 53% |
| Cesarean section | 6 | 754/4372 vs 1955/10436 | 1.09 (0.92–1.28) | 0.330 | 55% |
| Postpartum fever | 3 | 30/1756 vs 53/4942 | 1.18 (0.55–2.54) | 0.670 | 41% |
| Postpartum hemorrhage | 6 | 162/4372 vs 329/10436 | 0.98 (0.80–1.20) | 0.840 | 2% |
| Maternal ICU admission | 3 | 8/981 vs 12/3108 | 2.36 (0.96–5.78) | 0.060 | 0% |
| Chorioamnionitis | 2 | 14/843 vs 28/1456 | 0.79 (0.42–1.50) | 0.470 | 0% |
| Transfusions | 2 | 28/850 vs 224/2715 | 1.31 (0.85–2.02) | 0.220 | 0% |

Abbreviations: CI, confidence interval; ICU, intensive care unit; MD, mean difference; OR, odds ratio. Statistically significant values are put in bold.

**Figure 4**: Forest plot for the odds ratio of non-reassuring fetal monitoring.
women, showing also that vaccine-induced immunity was higher than infection-induced and that antibodies were also found in umbilical cord blood and breast milk.

Interestingly, it was also observed that the length of the time interval from vaccination to delivery influences the antibody titer in a directly proportional manner.\textsuperscript{50,51}

Likewise, an interesting objective for future research would be to clarify the impact of different vaccination timing on perinatal outcomes: Dick et al.\textsuperscript{54} showed an increased preterm birth rate and lower overall gestational age at delivery in women vaccinated during the second trimester compared with unvaccinated pregnant women. Goldshtein et al.\textsuperscript{35} observed no differences in the rate of preterm delivery, small-for-gestational-age neonate, and any congenital malformation between pregnant women vaccinated during the first trimester and unvaccinated pregnant women. Nevertheless, our results reflect the outcomes after second (mainly attributable to Goldshtein et al.\textsuperscript{35}) and third trimesters compared with unvaccinated pregnant women. However, no studies have yet evaluated directly the comparison of perinatal outcomes between trimesters.

Regarding the risk of miscarriage for first-trimester vaccination, Magnus et al.\textsuperscript{52} observed no increased risk, in accordance with Kharbanda et al.\textsuperscript{53} and Zauche et al.\textsuperscript{54} However, none of these studies could be included in our meta-analysis for various reasons (Table S3).

Another hint could be represented by the comparison among one or more doses, especially when we are going to consider the booster doses during pregnancy\textsuperscript{20}; in this regard, only Wainstock et al.\textsuperscript{37} performed a subgroup analysis, observing no differences in the rate of pregnancy-related hypertensive disorders, cesarean delivery, small for gestational age and neonatal respiratory complications, but a reduced birth weight and lower gestational age at delivery in pregnant women with only one dose compared with those with two doses. Currently, a booster dose is recommended by various guidelines on the management of COVID-19 during pregnancy.\textsuperscript{55}

The last two big waves of the pandemic have been dominated by the Delta and Omicron variants, with the former associated with a more severe course of infection during pregnancy compared with the pre-Delta variants\textsuperscript{56} and the last that showed a milder infection but still increased prevalence of adverse outcomes in the unvaccinated pregnant women, next to a tremendous increase in contagiousness,\textsuperscript{57} which again put under strain the healthcare systems involved in the management of affected cases. In our meta-analysis, we still observed differences among vaccinated and unvaccinated women in relation to their medical history or personal features (age, ethnicity), which demonstrates again the need for intervention at a national level with a large informative campaign and a proficient, expert, and non-directional but very exhaustive counseling by general practitioners and obstetricians, reinforced by real world data and pooled analyses with overall large samples showing the safety of mRNA vaccines towards maternal and fetal/neonatal health, to ensure that pregnant women would have all the useful and needed information to take their decision in an autonomous but very conscious way.\textsuperscript{58,59} Magee et al.\textsuperscript{60} calculated in 11 the number of

### Table 5

Mean difference and pooled odds ratio (with 95% confidence intervals) for fetal and neonatal outcomes of pregnant women undergoing COVID-19 vaccination compared with those who remained unvaccinated

| Fetal                                      | Studies | Fetuses \((n_f/N_f) vs n_i/N_i\) | Pooled OR (95% CI) | \(P\) value | \(I^2\) |
|--------------------------------------------|---------|---------------------------------|--------------------|-------------|--------|
| Stillbirth                                 | 4       | 25/3288 vs 45/6631              | 0.96 (0.58–1.57)   | 0.860       | 0%     |
| SGA                                        | 6       | 1255/19871 vs 866/14011         | 0.97 (0.85–1.09)   | 0.570       | 15%    |
| Non-reassuring fetal monitoring            | 2       | 53/1086 vs 278/4015             | 0.69 (0.51–0.94)   | 0.020       | 1%     |
| Oligohydramnios                            | 2       | 31/1086 vs 127/4015             | 0.90 (0.60–1.34)   | 0.610       | 0%     |
| Polyhydramnios                             | 2       | 12/1086 vs 37/4015              | 1.15 (0.60–2.23)   | 0.670       | 0%     |
| Meconium-stained amniotic fluid            | 2       | 130/1625 vs 336/4549            | 0.78 (0.58–1.03)   | 0.080       | 32%    |
| Abnormal presentation                      | 2       | 43/1086 vs 155/4015             | 1.02 (0.73–1.45)   | 0.890       | 0%     |

| Neonatal                                   | Studies | Infant born \((n_f/N_f) vs n_i/N_i\) | Pooled OR (95% CI) | \(P\) value | \(I^2\) |
|--------------------------------------------|---------|---------------------------------|--------------------|-------------|--------|
| Neonatal birth weight                      | 5       | 12652                           | −2.74 (−3.08 to 25.37) | 0.850 | 61%    |
| NICU admission                             | 4       | 41/1073 vs 82/3174              | 0.94 (0.63–1.40)   | 0.760       | 0%     |
| 5-min Apgar <7                             | 5       | 69/4241 vs 157/10043            | 0.95 (0.69–1.29)   | 0.740       | 1%     |
| Respiratory complications                  | 3       | 16/1798 vs 76/5078              | 0.67 (0.31–1.46)   | 0.310       | 16%    |
| Fever                                      | 2       | 4/1086 vs 13/4015               | 1.05 (0.34–3.24)   | 0.930       | 0%     |
| Jaundice                                   | 2       | 203/16349 vs 87/6290            | 0.91 (0.32–2.55)   | 0.850       | 90%    |
| LBW                                        | 2       | 686/15775 vs 368/6879           | 0.89 (0.77–1.03)   | 0.120       | 0%     |
| VLBW                                       | 2       | 51/15775 vs 56/6879            | 0.78 (0.22–2.81)   | 0.710       | 75%    |

Abbreviations: CI, confidence interval; LBW, low birth weight; MD, mean difference; NICU, neonatal intensive care unit; OR, odds ratio; SGA, small for gestational age; VLBW, very low birth weight. Statistically significant values are put in bold.
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

REFERENCES

1. Franchi M, Bosco M, Garzon S, et al. Management of obstetrics and gynaecological patients with COVID-19. *Italian J Obstet Gynecol*. 2020;32(1):6-19. doi:10.36129/jog.32.01.01

2. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. *Am J Obstet Gynecol*. 2020;222(5):415-426. doi:10.1016/j.ajog.2020.02.017

3. Carbone IF, Conforti A, Farina A, Alviggi C. A practical approach for the management of obstetric and infertile women during the phase two of the novel coronavirus disease 2019 (COVID-19) pandemic. *Eur J Obstet Gynecol Reprod Biol*. 2020;251:266-267. doi:10.1016/j.ejogrb.2020.06.006

4. Carbone L, Raffone A, Travaglino A, et al. Obstetric aSE unit admission and hospitalization for obstetrical management during COVID-19 pandemic in a third-level hospital of southern Italy. *Arch Gynecol Obstet*. 2021;291:1-9. doi:10.1007/s00404-021-06212-6

5. Picarelli S, Conforti A, Buonfante C, et al. IVF during coronavirus pandemic: who comes first? The POSEIDON viewpoint. *Italian J Gynaecol Obstet*. 2020;32(4):223-228. doi:10.36129/jog.32.04.01

6. Alviggi C, Esteves SC, Orvieto R, et al. POSEIDON (patient-oriented strategies encompassing Individualized oocyte number) group. COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management. *Reprod Biol Endocrinol*. 2020;18(1):45. doi:10.1186/s12958-020-00605-z

7. Carbone L, Raffone A, Sarno L, et al. Invasive prenatal diagnosis during COVID-19 pandemic. *Arch Gynecol Obstet*. 2021:305:797-801. doi:10.1007/s00404-021-06276-4

8. Carbone L, Esposito R, Raffone P, Carbone IF, Saccone G. Proposal for radiologic diagnosis and follow-up of COVID-19 in pregnant women. *J Matern Fetal Neonatal Med*. 2020;16:1-2. doi:10.1080/14767058.2020.1793325

9. Carbone L, Conforti A, LA Marca A, et al. The negative impact of most relevant infections on fertility and assisted reproduction technology. *Minerva Obstet Gynecol*. 2021. doi:10.23736/S2724-606X.21.04870-3

10. Oakes MC, Kernberg AS, Carter EB, et al. Pregnancy as a risk factor for severe coronavirus disease 2019 using standardized clinical criteria. *Am J Obstet Gynecol MFM*. 2021;3(3):100319. doi:10.1016/j.ajogmf.2021.100319

11. Sakowicz A, Ayala AE, Ukeje CC, Witting CS, Grobman WA, Miller ES. Risk factors for severe acute respiratory syndrome coronavirus-2 infection in pregnant women. *Am J Obstet Gynecol MFM*. 2020;2(4):100198. doi:10.1016/j.ajogmf.2020.100198

12. Di Mascio D, Sen C, Saccone G, et al. Risk factors associated with adverse fetal outcomes in pregnancies affected by coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19. *J Perinat Med*. 2020;48(9):950-958. Erratum in: *J Perinat Med* 2020 Dec 02;49(1):111–115. doi:10.1515/jpm-2020-0355

13. WAPM (World Association of Perinatal Medicine) Working Group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection. *Ultrasound Obstet Gynecol*. 2021;57(2):232-241. doi:10.1002/uog.23107

14. Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. 2021;3(6):100468. doi:10.1016/j.ajogmf.2021.100468

15. Chmielewska B, Barratt I, Townsend R, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9(6):e759-e772. Erratum in: *Lancet Glob Health*. 2021 Jun;9(6):e758. doi:10.1016/S2214-109X(21)00079-6

16. Pathirathna ML, Samarasekara BPP, Dasanayake TS, Saravanakumar P, Weerasekara I. Adverse perinatal outcomes in COVID-19 infected pregnant women needed to vaccinate (NNV) to prevent a SARS-CoV-2 infection, in 206 the NNV to prevent a symptomatic infection, as well as in 176 the NNV to prevent a preterm birth.

Additional studies with larger samples and longer follow ups are needed to uncover the doubts in relation to all the aspects of vaccination, from immunogenicity to adverse events and obstetrical and perinatal outcomes. However, the current findings support the safety of mRNA vaccines regarding pregnancy and delivery complications. In this scenario, it is of paramount importance that governments adopt all the needed strategies to inform this subgroup of the population that the consequences of the disease may be significantly more severe than the potential and unproven consequences of the vaccine, which are causing pregnant women’s avoidance. Furthermore, reporting of the acceptance/refusal of the vaccine against SARS-CoV-2 in all obstetrical and delivery settings will help to acquire more data on the safety of it, to be shared as soon as possible.

In conclusion, the probability of small for gestational age and other adverse perinatal outcomes is similar between vaccinated and unvaccinated pregnant women, who did not acquire COVID-19 during pregnancy. Furthermore, the rate of preterm delivery seems reduced among vaccinated pregnant women compared with their counterparts. These data strengthen the safety of the mRNA vaccines during pregnancy and should be used during professional counseling. Further data are needed to explore the impact of multiple doses (including booster) on perinatal outcomes and the difference between trimesters, taking into account the interval from vaccination to delivery.

AUTHOR CONTRIBUTIONS

LC, GS, and GMM contributed to study conception, study design, methods supervision, manuscript preparation, and whole study supervision. MGT contributed to data extraction, data analysis, and manuscript preparation. RDG contributed to study conception, study design, study methods, data extraction, data analysis, and manuscript preparation. AR contributed to study design, data analysis, manuscript preparation, and methods supervision. GGI contributed to study conception, study design, study methods, data analysis, and manuscript preparation. OG contributed to study design, study methods, data analysis, and manuscript preparation. GMM contributed to study conception, study design, methods supervision, manuscript preparation, and whole study supervision. All authors approved of the final of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

CONFLICT OF INTEREST

The authors report no conflict of interest.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.
pregnant women: a systematic review and meta-analysis. *Healthcare (Basel)*. 2022;10(2):203. doi:10.3390/healthcare10020203

17. The American College of Obstetricians and Gynecologists. ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals. [ACOG website]. 2021. Accessed June 22, 2022. https://www.acog.org/news/newsreleases/2021/07/acog-smfm-recommend-covid-19-vaccination-for-pregnant-individuals

18. Centers for Disease Control and Prevention. COVID-19 Vaccines While Pregnant or Breastfeeding. [CDC website]. 2022. Accessed June 22, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html

19. The Royal College of Obstetricians and Gynaecologists. Vaccination, [RCOG website]. 2021. Accessed June 22, 2022. https://www.rcog.org.uk/covid-vaccine

20. Kalafat E, Magee LA, von Dadelszen P, Heath P, Khalil A. COVID-19 booster doses in pregnancy and global vaccine equity. *Lancet*. 2022. doi:10.1016/S0140-6736(22)00166-0

21. Zavala E, Krubiner CB, Jaffe EF, et al. Global disparities in public health guidance for the use of COVID-19 vaccines in pregnancy. *BMJ Glob Health*. 2022;7(2):e007730. doi:10.1136/bmjgh-2021-007730

22. Mappa I, Luviso M, Distefano FA, Carbone L, Maruotti GM, Rizzo G. Women perception of SARS-CoV-2 vaccination during pregnancy and subsequent maternal anxiety: a prospective observational study. *J Matern Fetal Neonatal Med*. 2021;11:1-4. doi:10.1080/14767058.2021.1910672

23. Carbone L, Mappa I, Sirico A, et al. Pregnant women perspectives on SARS-CoV-2 vaccine: condensation: most of Italian pregnant women would not agree to get the SARS-CoV-2 vaccine, irrespective of having features of high risk themselves, or being high-risk pregnancies. *Am J Obstet Gynecol MFM*. 2021;23:100352. doi:10.1016/j.ajogmf.2021.100352

24. Carbone L, Di Girolamo R, Mappa I. Et. Worldwide beliefs among pregnant women on SARS-CoV-2 vaccine: a systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2022;268:144-164. doi:10.1016/j.ejogrb.2021.12.003

25. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol*. 2021. doi:10.1016/j.ajog.2021.03.023

26. Collier AY, McMahan K, Yu J, et al. Immunogenicity of SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. *J Clin Invest*. 2021;131(13):e150319. Erratum in: *J Clin Invest* 2021 Oct 1;131(19). doi:10.1172/JCI150319

27. Dick A, Rosenbloom JL, Gutman-Ido E, Lessans N, Cahen-Peretz A, Chih HH. Safety of SARS-CoV-2 vaccination during pregnancy: obstetric outcomes from a large cohort study. *BMC Pregnancy Childbirth*. 2022;22(1):166. doi:10.1186/s12884-022-04505-5

28. Wainstock T, Yoles I, Sergienko R, Sheiner E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. *Vaccine*. 2021;39(41):6037-6040. doi:10.1016/j.vaccine.2021.09.012

29. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in pregnancy: measures of immunity and placental histopathology. *Obstet Gynecol*. 2021;138(2):281-283. doi:10.1097.AOG.0000000000004457

30. Theiler RN, Wick M, Mehta R, Weaver AL, Virk A, Swift M. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. *Am J Obstet Gynecol MFM*. 2021;3(6):100467. doi:10.1016/j.ajogmf.2021.100467

31. Citu IM, Citu C, Gorun F, et al. Immunogenicity following administration of BNT162b2 and Ad26.COV2.S COVID-19 vaccines in the pregnant population during the third trimester. *Viruses*. 2022;14(2):307. doi:10.3390/v14020307

32. Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination during pregnancy: coverage and safety. *Am J Obstet Gynecol*. 2022;226(2):e236.e1-236.e14. doi:10.1016/j.ajog.2021.08.007

33. Garcia R, Ali N, Papadopoulos C, Randhawa G. Specific antenatal interventions for black, Asian and minority ethnic (BAME) pregnant women at high risk of poor birth outcomes in the United Kingdom: a scoping review. *BMJ Pregnancy Childbirth*. 2015;24(15):226. doi:10.1136/s12884-015-0567-2

34. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(1):26-30. doi:10.15585/mmwr.mm7101e1

35. The National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. [NICE website]. 2022. Accessed June 22, 2022. https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-pdf-51038446021

36. Ma Y, Deng J, Liu Q, Du M, Liu M, Liu J. Effectiveness and safety of COVID-19 vaccine among pregnant women in real-world studies: a systematic review and meta-analysis. *Vaccines (Basel)*. 2022;10(2):246. doi:10.3390/vaccines10020246
48. Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. mRNA Covid-19 vaccines in pregnancy: a systematic review. PLoS One. 2022;17(2):e0261350. doi:10.1371/journal.pone.0261350

49. Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021;58(3):450-456. doi:10.1002/uog.23729

50. Kugelman N, Nahshon C, Shaked-Mishan P, et al. Maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at delivery after receipt of the BNT162b2 messenger RNA COVID-19 vaccine during the second trimester of pregnancy. JAMA Pediatr. 2022;176(3):290-295. doi:10.1001/jamapediatrics.2021.5683

51. Zdanowski W, Waśniewski T. Evaluation of SARS-CoV-2 spike protein antibody titers in cord blood after COVID-19 vaccination during pregnancy in polish healthcare workers: preliminary results. Vaccines (Basel). 2021;9(6):675. doi:10.3390/vaccines9060675

52. Magnus MC, Gjessing HK, Eide HN, Wilcox DB, Håberg SE. Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med. 2021;385(21):2008-2010. doi:10.1056/NEJMc2114466

53. Kharbanda EO, Haapala J, DeSilva M, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA. 2021;326(16):1629-1631. Erratum in: JAMA 2021 Sep 10. doi:10.1001/jama.2021.15494

54. Zauche LH, Wallace B, Smoots AN, et al. CDC v-safe Covid-19 pregnancy registry team. Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion. N Engl J Med. 2021;385(16):1533-1535. doi:10.1056/NEJMc2113891

55. Di Girolamo R, Khalil A, Rizzo G, et al. Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. Am J Obstet Gynecol MFM. 2022;4(5):100654. doi:10.1016/j.ajogmf.2022.100654

56. Seasey AR, Blanchard CT, Arora N, et al. Maternal and perinatal outcomes associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) variant. Obstet Gynecol. 2021;138(6):842-844. doi:10.1097/AOG.0000000000004607

57. Birol Ilter P, Prasad S, Berkkan M, et al. Clinical severity of SARS-CoV-2 infection among vaccinated and unvaccinated pregnancies during the omicron wave. Ultrasound Obstet Gynecol. 2022;59:560-562. doi:10.1002/uog.24893

58. Di Mascio D, Buca D, Berghella V, et al. Counseling in maternal-fetal medicine: SARS-CoV-2 infection in pregnancy. Ultrasound Obstet Gynecol. 2021;57(5):687-697. doi:10.1002/uog.23628

59. Chervenak FA, McCullough LB, Bornstein E, et al. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients. Am J Obstet Gynecol. 2021;224(5):470-478. doi:10.1016/j.ajog.2021.01.027

60. Magee LA, von Dadelszen P, Kalafat E, et al. COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm. Lancet Infect Dis. 2021;21(12):1627. doi:10.1016/S1473-3099(21)00691-5

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Carbone L, Trinchillo MG, Di Girolamo R, et al. COVID-19 vaccine and pregnancy outcomes: A systematic review and meta-analysis. Int J Gynecol Obstet. 2022;159:651-661. doi: 10.1002/ijgo.14336